The presentation focuses on *Turning Cyanotoxins into drugs*, specifically exploring microcystins as novel payloads for antibody-drug conjugates. It highlights how natural products from cyanobacteria, including cyanotoxins, exhibit impressive biological activity, making them valuable for drug development. Examples such as dolastatins and microcystins are discussed, showcasing their potential as therapeutic agents despite their toxic nature. The innovative use of these molecules in biotechnological and pharmaceutical applications underscores the promise of cyanobacteria in drug discovery.
